Episode
Klotho: The Longevity Hormone You've Never Heard Of | Age-Less Top 20 Peptides
- Published
- May 27, 2026
- Duration seconds
- 1302
- Processing state
not_requested- Canonical source
- https://rss.com/podcasts/the-science-of-age-less-living/2862282
Actions
POST https://stenobird.com/v1/public/podcasts/the-science-of-age-less-living-7235688/episodes/klotho-the-longevity-hormone-you-ve-never-heard-of-age-less-top-20-peptides/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-science-of-age-less-living-7235688/klotho-the-longevity-hormone-you-ve-never-heard-of-age-less-top-20-peptides.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Klotho was discovered in 1997 when a disrupted gene caused mice to develop every hallmark of premature ageing within weeks — osteoporosis, arteriosclerosis, muscle wasting, cognitive decline — and die at a fraction of their expected lifespan. The inverse experiment extended lifespan by twenty to thirty percent. The protein was named after Clotho, the Greek Fate who spins the thread of life. It remains one of the most studied proteins in longevity biology nearly three decades later. In this episode, Dr. Ethan Hausman-Marquis examines Klotho from the ground up: the critical distinction between transmembrane α-Klotho and its circulating shed form sKlotho; how the FGF23 co-receptor mechanism explains the accelerated ageing phenotype of Klotho deficiency; what five separate longevity-associated pathways — including IGF-1/PI3K suppression, Wnt/β-catenin inhibition, Nrf2 antioxidant activation, and TGF-beta fibrosis suppression — suggest about why this protein matters so broadly; and why circulating Klotho levels decline by approximately 40 percent between the ages of 40 and 80. The human evidence is examined honestly: what the large prospective cohort studies actually show, what the KL-VS genetic variant data adds to the causal argument, what the 2014 Cell Reports cognitive findings mean for neurodegeneration research, and why the interventional human data — despite the extraordinary preclinical picture — is essentially non-existent. The evidence base, the interventional frontier, the exercise and vitamin D data, and the honest assessment of where exogenous Klotho research actually stands in 2026 — all of it, examined without hype. If you're researching Klotho supplementation, Klotho and ageing, Klotho and cognitive decline, or the science behind longevity peptides and anti-…